Abstract:<h3 class="Heading">Purpose</h3><p class="Para">To compare annotation segmentation approaches and to assess the value of radiomics analysis applied to diffusion-weighted imaging (DWI) for evaluation of breast cancer receptor status and molecular subtyping.</p><h3 class="Heading">Procedures</h3><p class="Para">In this IRB-approved HIPAA-compliant retrospective study, 91 patients with treatment-naïve breast malignancies proven by image-guided breast biopsy, (luminal A, <em class="EmphasisTypeItalic">n</em> = 49; luminal B, <em class="EmphasisTypeItalic">n</em> = 8; human epidermal growth factor receptor 2 [HER2]-enriched, <em class="EmphasisTypeItalic">n</em> = 11; triple negative [TN], <em class="EmphasisTypeItalic">n</em> = 23) underwent multiparametric magnetic resonance imaging (MRI) of the breast at 3 T with dynamic contrast-enhanced MRI, T2-weighted and DW imaging. Lesions were manually segmented on high b-value DW images and segmentation ROIS were propagated to apparent diffusion coefficient (ADC) maps. In addition in a subgroup (<em class="EmphasisTypeItalic">n</em> = 79) where lesions were discernable on ADC maps alone, these were also directly segmented there. To derive radiomics signatures, the following features were extracted and analyzed: first-order histogram (HIS), co-occurrence matrix (COM), run-length matrix (RLM), absolute gradient, autoregressive model (ARM), discrete Haar wavelet transform (WAV), and lesion geometry. Fisher, probability of error and average correlation, and mutual information coefficients were used for feature selection. Linear discriminant analysis followed by k-nearest neighbor classification with leave-one-out cross-validation was applied for pairwise differentiation of receptor status and molecular subtyping. Histopathologic results were considered the gold standard.</p><h3 class="Heading">Results</h3><p class="Para">For lesion that were segmented on DWI and segmentation ROIs were propagated to ADC maps the following classification accuracies > 90% were obtained: luminal B <em class="EmphasisTypeItalic">vs.</em> HER2-enriched, 94.7 % (based on COM features); luminal B <em class="EmphasisTypeItalic">vs.</em> others, 92.3 % (COM, HIS); and HER2-enriched <em class="EmphasisTypeItalic">vs.</em> others, 90.1 % (RLM, COM). For lesions that were segmented directly on ADC maps, better results were achieved yielding the following classification accuracies: luminal B <em class="EmphasisTypeItalic">vs.</em> HER2-enriched, 100 % (COM, WAV); luminal A <em class="EmphasisTypeItalic">vs.</em> luminal B, 91.5 % (COM, WAV); and luminal B <em class="EmphasisTypeItalic">vs.</em> others, 91.1 % (WAV, ARM, COM).</p><h3 class="Heading">Conclusions</h3><p class="Para">Radiomic signatures from DWI with ADC mapping allows evaluation of breast cancer receptor status and molecular subtyping with high diagnostic accuracy. Better classification accuracies were obtained when breast tumor segmentations could be performed on ADC maps.</p>

Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer

Prediction Breast Molecular Typing of Invasive Ductal Carcinoma Based on Dynamic Contrast Enhancement Magnetic Resonance Imaging Radiomics Characteristics: A Feasibility Study

Potential of the Non-Contrast-Enhanced Chest CT Radiomics to Distinguish Molecular Subtypes of Breast Cancer: A Retrospective Study

Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics

A quantitative heterogeneity analysis approach to molecular subtype recognition of breast cancer in dynamic contrast-enhanced magnetic imaging images from radiomics data

Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer

Using ensemble learning and genetic algorithm on magnetic resonance imaging radiomics to classify molecular subtypes of breast cancer

Comparison of Dynamic Contrast‐Enhanced MRI and Non‐Mono‐Exponential Model‐Based Diffusion‐Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics

Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer

Intra- and Peritumoral Radiomics Model Based on Early DCE-MRI for Preoperative Prediction of Molecular Subtypes in Invasive Ductal Breast Carcinoma: A Multitask Machine Learning Study

Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes

Elaboration of a multimodal MRI-based radiomics signature for the preoperative prediction of the histological subtype in patients with non-small-cell lung cancer

Predicting Breast Cancer Subtypes Using Magnetic Resonance Imaging Based Radiomics with Automatic Segmentation.

Molecular subtypes of breast cancer identified by dynamically enhanced MRI radiomics: the delayed phase cannot be ignored

Radiomics Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Sentinel Lymph Node Metastasis in Breast Cancer

Correlation of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted MR Imaging with Prognostic Factors and Subtypes of Breast Cancers.

Decoding Breast Cancer: Using Radiomics to Non-Invasively Unveil Molecular Subtypes Directly from Mammographic Images

Non-Mass Enhancements on DCE-MRI: Development and Validation of a Radiomics-Based Signature for Breast Cancer Diagnoses

Clinical-radiomics nomogram based on the fat-suppressed T2 sequence for differentiating luminal and non-luminal breast cancer

Application of Digital Mammography-Based Radiomics in the Differentiation of Benign and Malignant Round-Like Breast Tumors and the Prediction of Molecular Subtypes